Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI119145

Chemokine receptor usage by human eosinophils. The importance of CCR3 demonstrated using an antagonistic monoclonal antibody.

H Heath, S Qin, P Rao, L Wu, G LaRosa, N Kassam, P D Ponath, and C R Mackay

LeukoSite, Inc., Cambridge, Massachusetts 02142, USA.

Find articles by Heath, H. in: JCI | PubMed | Google Scholar

LeukoSite, Inc., Cambridge, Massachusetts 02142, USA.

Find articles by Qin, S. in: JCI | PubMed | Google Scholar

LeukoSite, Inc., Cambridge, Massachusetts 02142, USA.

Find articles by Rao, P. in: JCI | PubMed | Google Scholar

LeukoSite, Inc., Cambridge, Massachusetts 02142, USA.

Find articles by Wu, L. in: JCI | PubMed | Google Scholar

LeukoSite, Inc., Cambridge, Massachusetts 02142, USA.

Find articles by LaRosa, G. in: JCI | PubMed | Google Scholar

LeukoSite, Inc., Cambridge, Massachusetts 02142, USA.

Find articles by Kassam, N. in: JCI | PubMed | Google Scholar

LeukoSite, Inc., Cambridge, Massachusetts 02142, USA.

Find articles by Ponath, P. in: JCI | PubMed | Google Scholar

LeukoSite, Inc., Cambridge, Massachusetts 02142, USA.

Find articles by Mackay, C. in: JCI | PubMed | Google Scholar

Published January 15, 1997 - More info

Published in Volume 99, Issue 2 on January 15, 1997
J Clin Invest. 1997;99(2):178–184. https://doi.org/10.1172/JCI119145.
© 1997 The American Society for Clinical Investigation
Published January 15, 1997 - Version history
View PDF
Abstract

Chemokines bind and signal through G-protein coupled seven transmembrane receptors. Various chemokine receptors are expressed on leukocytes, and these may impart selective homing of leukocyte subsets to sites of inflammation. Human eosinophils express the eotaxin receptor, CCR3, but respond to a variety of CC chemokines apart from eotaxin, including RANTES, monocyte chemotactic protein (MCP)-2, MCP-3, and MCP-4. Here we describe a mAb, 7B11, that is selective for CCR3 and has the properties of a true receptor antagonist. 7B11 blocked binding of various radiolabeled chemokines to either CCR3 transfectants, or eosinophils. Pretreatment of eosinophils with this mAb blocked chemotaxis and calcium flux induced by all CCR3 ligands. In all individuals examined, including allergic and eosinophilic donors, > 95% of the response of eosinophils to eotaxin, RANTES, MCP-2, MCP-3, and MCP-4 was shown to be mediated through CCR3. The IL-8 receptors, particularly CXCR2, were induced on IL-5 primed eosinophils, however these eosinophils responded to CC chemokines in the same manner as unprimed eosinophils. These results demonstrate the importance of CCR3 for eosinophil responses, and the feasibility of completely antagonizing this receptor.

Version history
  • Version 1 (January 15, 1997): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts